• BridgeBio published new clinical data on acoramidis from Phase 3 ATTRibute-CM, focusing on an integrated Month 30 endpoint combining survival with Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) health-status outcomes in ATTR cardiomyopathy.
• Acoramidis showed higher odds versus placebo for being alive with stable or improved KCCQ-OS at Month 30 (OR 1.8; 95% CI 1.3-2.6) and for being “alive and well” (OR 1.9; 95% CI 1.3-2.8).
• Measures of improvement also favored acoramidis, including “alive and better” (OR 2.1; 95% CI 1.4-3.1) and a reported number needed to treat of 7 (95% CI 4.5-16.2) for “alive and better.”
• Separate results cited a 9.9-point least-squares mean benefit in KCCQ-OS decline through Month 30 versus placebo (95% CI 6.0-13.9; p<0.001) and a higher share of patients with net KCCQ-OS improvement (31% vs 18%).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 09, 2026, and is solely responsible for the information contained therein.